Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

PFE sits at a Zacks Rank #3 (Hold), holds a Momentum Style Score of B, and has a VGM Score of A. The stock is down 0.8% and up 5.2% over the past one-week and four-week period, respectively ...

Pfizer (PFE) closed the latest trading day at $26.61, indicating a +0.3% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 0.22%. Elsewhere ...

PFE returned $7.1 billion via dividends in 9M-24, while reducing debt by $4.4 billion through balance sheet optimization. Investing $10.7-$11.7 billion in R&D, focusing on obesity treatments ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been one of Jim ...

Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go.

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other dividend stocks. AI stocks are stealing the spotlight today as the appetite for these services ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares closed yesterday at $25.57. Pick the best stocks and ...